Program
olaparib
Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 5915 open or running | phase 4since Jun 10, 2015 | Jun 27, 2007 | Apr 6, 2027phase 3 · NCT04421963 |
| Merck | 125 open or running | phase 3since Mar 29, 2018 | Aug 3, 2016 | May 5, 2027phase 3 · NCT04380636 |
| Novartis | 20 open or running | phase 3since Jan 25, 2021 | Jan 25, 2021 | none ahead |
| Boryung Pharmaceutical | 11 open or running | phase 1since Jul 7, 2025 | Jul 7, 2025 | none ahead |
| CSPC Pharmaceutical Group | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
| Daewoong Pharmaceutical | 11 open or running | phase 1since Jan 19, 2026 | Jan 19, 2026 | Mar 2027phase 1 · NCT07371104 |
Also a collaborator on its studies: myriad-genetic-laboratories-inc, frontier-science-technology-research-foundation-inc, Hoffmann-La Roche, myriad-genetics-inc, iqvia-pty-ltd, covance, theradex, parexel and kudos-pharmaceuticals-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 7, 2009.
- Mar 30, 2020Phase 4 study in Ovarian NeoplasmsAstraZeneca · NCT04330040 · 202 enrolled · India
- May 5, 2020Phase 3 study in Lung NeoplasmsMerck · NCT04380636 · 870 enrolled · United States, Argentina, Canada and more
- May 19, 2020Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963 · 185 enrolled · United States, Belgium, Bulgaria and more
- Jul 1, 2020Phase 3 study in Colorectal NeoplasmsMerck · NCT04456699 · 335 enrolled · United States, Australia, Belgium and more
- Nov 5, 2020Phase 3 study in Small Cell Lung CarcinomaMerck · NCT04624204 · 672 enrolled · United States, Australia, Belgium and more
- Jan 25, 2021Novartis's first study: phase 3 study in Ovarian NeoplasmsNew to NovartisNovartis · NCT04729387 · 358 enrolled · United States, Argentina, Australia and more
- Apr 20, 2021Phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04884360 · 366 enrolled · Chile, China, Colombia and more
- Dec 20, 2021Phase 3 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05171816 · 110 enrolled · China
- Feb 17, 2022Phase 1 study in Ovarian NeoplasmsNovartis · NCT05258747 · 70 enrolled · India
- Jul 5, 2022Phase 2 study in Breast NeoplasmsAstraZeneca · NCT05498155 · 50 enrolled · United States, Australia, Austria and more
- Jul 11, 2022Phase 4 study in Metastatic Castration-resistant Prostate CancerAstraZeneca · NCT05457257 · 43 enrolled · China
- Apr 7, 2024CSPC Pharmaceutical Group's first study: phase 1 study in Healthy ParticipantsNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06360445 · 102 enrolled · China
- Jul 7, 2025Boryung Pharmaceutical's first study: phase 1 study in Ovarian NeoplasmsNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07069335 · 24 planned · South Korea
- Jan 19, 2026Daewoong Pharmaceutical's first study: phase 1 study in NeoplasmsNew to Daewoong PharmaceuticalDaewoong Pharmaceutical · NCT07371104 · 40 planned · South Korea
Ahead
- Mar 2027Primary completion: phase 1 study in NeoplasmsDaewoong Pharmaceutical · NCT07371104
- Apr 6, 2027Primary completion: phase 3 study in Ovarian NeoplasmsAstraZeneca · NCT04421963
- May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsMerck · NCT04380636
- Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerMerck · NCT02861573
TargetBeta
“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 76 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07371104Neoplasms · South Korea | 1 | Recruiting | Daewoong Pharmaceutical | Mar 2027 | 40 |
| NCT07069335Ovarian Neoplasms · South Korea | 1 | Recruiting | Boryung Pharmaceutical | May 15, 2026 | 24 |
| NCT06360445Healthy Participants · China | 1 | Completed | CSPC Pharmaceutical Group | Aug 21, 2022 | 102 |
| NCT05457257Metastatic Castration-resistant Prostate Cancer · China | 4 | Active, not recruiting | AstraZeneca | Oct 22, 2024 | 43 |
| NCT05498155Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | AstraZeneca | Nov 20, 2024 | 50 |
| NCT05258747Ovarian Neoplasms · India | 1 | Completed | Novartis | Oct 20, 2022 | 70 |
| NCT05171816Metastatic Castration-resistant Prostate Cancer · China | 3 | Active, not recruiting | AstraZeneca | Jan 22, 2024 | 110 |
| NCT04884360Ovarian Neoplasms · Chile, China, Colombia and more | 3 | Active, not recruiting | AstraZeneca | Jul 27, 2026 | 366 |
| NCT04729387Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Novartis | Apr 21, 2023 | 358 |
| NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | Merck | Oct 28, 2027 | 672 |
| NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Mar 27, 2023 | 335 |
| NCT04421963Ovarian Neoplasms · United States, Belgium, Bulgaria and more | 3 | Active, not recruiting | AstraZeneca | Apr 6, 2027 | 185 |
| NCT04380636Lung Neoplasms · United States, Argentina, Canada and more | 3 | Active, not recruiting | Merck | May 5, 2027 | 870 |
| NCT04330040Ovarian Neoplasms · India | 4 | Completed | AstraZeneca | Sep 30, 2022 | 202 |
| NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 8, 2024 | 805 |
| NCT04239014Ovarian Neoplasms · United States, Canada, Italy and more | 2 | Withdrawn | AstraZeneca | Jan 25, 2021 | 0 |
| NCT04191135Triple Negative Breast Neoplasms · United States, Canada, Chile and more | 2 | Terminated | Merck | Dec 15, 2022 | 462 |
| NCT04236414Neoplasms · Denmark, France, Germany and more | 1 | Completed | AstraZeneca | Feb 4, 2025 | 16 |
| NCT04123366Solid Tumors · United States, Argentina, Australia and more | 2 | Completed | Merck | Jun 8, 2026 | 333 |
| NCT03976362Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Merck | Sep 21, 2023 | 851 |
| NCT03976323Carcinoma · United States, Argentina, Australia and more | 3 | Completed | Merck | Feb 7, 2024 | 1,003 |
| NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merck | Mar 14, 2022 | 793 |
| NCT03775486Non-small Cell Lung Cancer NSCLC · United States, Belgium, Hungary and more | 2 | Active, not recruiting | AstraZeneca | Jan 11, 2021 | 401 |
| NCT03742895Advanced Solid Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Merck | Aug 12, 2025 | 329 |
| NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Aug 26, 2024 | 1,367 |
| NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Mar 17, 2025 | 1,407 |
| NCT03732820Metastatic Castration-resistant Prostate Cancer · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Jul 30, 2021 | 895 |
| NCT03553108Malignant Solid Tumor · Belgium | 1 | Completed | AstraZeneca | Mar 12, 2019 | 18 |
| NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Merck | Aug 4, 2043 | 3,500 |
| NCT03534453Ovarian Neoplasms · China, Malaysia | 3 | Completed | AstraZeneca | Jan 27, 2025 | 225 |
| NCT03459846Urinary Bladder Neoplasms · United States, Canada, Russia and more | 2 | Active, not recruiting | AstraZeneca | Oct 15, 2020 | 154 |
| NCT03402841Ovarian Neoplasms · Austria, Belgium, Bulgaria and more | 3 | Completed | AstraZeneca | Oct 2, 2020 | 279 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | AstraZeneca | Sep 13, 2024 | 528 |
| NCT03286842HER2-ve Metastatic Breast Cancer · United States, Bulgaria, Canada and more | 3 | Completed | AstraZeneca | Oct 8, 2021 | 256 |
| NCT03106987Carcinoma, Ovarian Epithelial · Belgium, Canada, Denmark and more | 3 | Completed | AstraZeneca | Feb 15, 2021 | 220 |
| NCT03022409Squamous Cell Carcinoma of Head and Neck · United States, France, Taiwan | 1 | Completed | AstraZeneca | Jan 20, 2021 | 21 |
| NCT02987543Metastatic Castration-resistant Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jun 4, 2019 | 387 |
| NCT02983799Ovarian Neoplasms · United States, Canada | 2 | Completed | AstraZeneca | Dec 3, 2020 | 272 |
| NCT02861573Metastatic Castration-Resistant Prostate Cancer | 2 | Active, not recruiting | Merck | Oct 22, 2027 | 1,200 |
| NCT02561832Breast Neoplasms · United States, Spain | 1 | Terminated | AstraZeneca | Sep 30, 2016 | 15 |
| NCT02476968BRCA or HRR+ Mutated Ovarian Cancer Patients · Bulgaria, Canada, Czechia and more | 4 | Completed | AstraZeneca | Apr 17, 2020 | 181 |
| NCT02430311Advanced Solid Tumours · China | 1 | Completed | AstraZeneca | Jul 27, 2016 | 36 |
| NCT02392676Ovarian Neoplasms · United States, Korea, Republic of, Peru and more | 3 | Withdrawn | AstraZeneca | Jun 2019 | 0 |
| NCT02282020Ovarian Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Oct 10, 2018 | 266 |
| NCT02184195Pancreatic Neoplasms · United States, Australia, Belgium and more | 3 | Completed | AstraZeneca | Jan 15, 2019 | 154 |
| NCT02093351Neoplasms · Belgium, Denmark, France and more | 1 | Completed | AstraZeneca | Apr 30, 2015 | 79 |
| NCT02032823Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Mar 27, 2020 | 1,837 |
| NCT02000622Breast Neoplasms · United States, Bulgaria, China and more | 3 | Completed | AstraZeneca | Dec 9, 2016 | 302 |
| NCT01972217Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | AstraZeneca | Sep 22, 2017 | 158 |
| NCT01924533Stomach Neoplasms · China, Japan, Korea, Republic of and more | 3 | Completed | AstraZeneca | Apr 4, 2016 | 525 |
| NCT01921140Neoplasms · Belgium, Denmark, Netherlands and more | 1 | Completed | AstraZeneca | Apr 8, 2014 | 60 |
| NCT01874353Ovarian Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Sep 19, 2016 | 327 |
| NCT01851265Neoplasms · Belgium, Netherlands, United Kingdom | 1 | Completed | AstraZeneca | Oct 18, 2013 | 32 |
| NCT01844986Pathologic Complete Response · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | May 17, 2018 | 450 |
| NCT01813474Neoplasms · Japan | 1 | Completed | AstraZeneca | Aug 31, 2016 | 23 |
| NCT01078662Ovarian · United States, Australia, Germany and more | 2 | Completed | AstraZeneca | Jul 31, 2012 | 298 |
| NCT01081951Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Active, not recruiting | AstraZeneca | Oct 10, 2011 | 162 |
| NCT01063517Stomach Neoplasms · Korea, Republic of | 2 | Completed | AstraZeneca | May 11, 2012 | 124 |
| NCT00912743Colorectal Neoplasms · United States | 2 | Completed | AstraZeneca | Mar 2012 | 33 |
| NCT00819221Solid Tumors · Italy, Switzerland | 1 | Terminated | AstraZeneca | Nov 30, 2011 | 44 |
How it is read
Names in the registry
- “Olaparib”, 38 entries
- “olaparib”, 10 entries
- “AZD2281”, 10 entries
- “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
- “Olaparib 300mg tablets”, 3 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 24 studies
- Breast Neoplasms, 7 studies
- Prostatic Neoplasms, 7 studies
- Neoplasms, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.